HKG:2511

2 stories mentioning HKG:2511Updated 42d ago

Every FINWIRES story that references HKG:2511, newest first.

HighTide Therapeutics, CEO Terminate Loan Contract on Bourse's Concerns

HighTide Therapeutics (HKG:2511) and CEO Liu Liping as borrower agreed to terminate a HK$15 million loan agreement effective immediately.No amount was drawn under the loan facility, according to a Thursday bourse filing.The move came as the Hong Kong bourse raised concerns about non-compliance with the listing rules.The stock exchange said the facility may not be on normal commercial terms or better and a partial exemption should not have been applied at the time of the loan grant.The bourse said the deal should have been subject to a circular, independent financial advice, and shareholders' approval.

HKG:2511

Asia107d ago

HighTide Therapeutics Agrees to Lend HK$15 Million to CEO

HighTide Therapeutics (HKG:2511) agreed to lend up to HK$15 million to its CEO Liu Liping, it said in a Monday Hong Kong bourse filing.The pharmaceutical company's shares fell 1% in early afternoon trade Tuesday.Borrowings under the facility are payable a year from drawdown and will accrue interest at 3.50% per annum.

HKG:2511

Track with the FINWIRES app suite

FolioX

Track HKG:2511 in your portfolio

WheelAI

Analyze HKG:2511 options with the wheel strategy

StockInsider

See market sentiment on HKG:2511